NCT07324512
Minimum Effective Volume of Crystalloid Co-Loading to Prevent Spinal Anesthesia-Induced Hypotension in Cesarean Section
At risk: Primary completion moved 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from May 31, 2026 to May 31, 2027 Show 6 more changesShow less
- Recruitment opened
- Primary endpoints: details revised at 1 of 1 entry
- Eligibility criteria expanded, about 5 words
- Study completion pushed from Jun 30, 2026 to Jun 30, 2027
- Start date changed from estimate of Dec 27, 2025 to Jan 11, 2026
- Secondary endpoints: details revised at 14 of 15 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (15)
Show 10 moreShow less
Arms and interventions
Participants undergo spinal anesthesia for elective cesarean delivery. Immediately after intrathecal injection, a predefined volume of balanced crystalloid (co-loading) is infused over \~10 minutes while a prophylactic phenylephrine infusion is initiated per protocol. The crystalloid volume for each successive participant is adjusted using a biased-coin up-and-down algorithm to identify the minimum effective volume that prevents spinal-anesthesia-induced hypotension in ≥90% of patients (MEV90, mL/kg). Blood pressure is monitored frequently; rescue phenylephrine and/or fluids are permitted to maintain predefined blood pressure ranges. Maternal adverse events and neonatal outcomes are recorded through postoperative day 2.
Other: Intravenous Crystalloid Co-Loading
Sites
1 site in 1 country
- Seoul National University HospitalSeoul, South Korea